Prostate Cancer

The Prostate Cancer Foundation (PCF) Doctor-Patient Summit October 25, 2021

Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer October 25, 2021

Roche Launches Comprehensive Genomic Profiling Kit to Expand Access to Personalised Cancer Research October 25, 2021

Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. October 25, 2021

Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. October 25, 2021

Repeated MRIs during Active Surveillance: natural history of prostatic lesions and upgrading rates. October 25, 2021

DNMT3A epigenetically regulates key microRNAs involved in epithelial-to-mesenchymal transition in prostate cancer. October 25, 2021

Early Catheter Removal on Postoperative Day 2 After Robot-assisted Radical Prostatectomy: Updated Real-life Experience with the Aalst Technique. October 25, 2021

On site production of [18F]PSMA-1007 using different [18F]fluoride activities: practical, technical and economical impact. October 22, 2021

Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer. October 22, 2021

Reorganization of the 3D genome pinpoints non-coding drivers of primary prostate tumors. October 22, 2021

Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Prostate Cancer. October 22, 2021

Can Pre-treatment Quantitative Multi-parametric MRI Predict the Outcome of Radiotherapy in Patients with Prostate Cancer? October 22, 2021

Reflections on Fellowship Training for Community-Based Practice October 21, 2021

Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials. October 21, 2021

P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. October 21, 2021

Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes. October 21, 2021

Excellent Response to Adapted Low-Dose 177Lu-PSMA-617 PSMA Therapy in Renal Compromise Patient. October 21, 2021

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial. October 21, 2021

Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact. October 20, 2021

Page 1 of 1182

email news signup